Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Olin

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Cancer Chemotherapy and Pharmacology|March 10, 2012
9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant gliomaAaron M Teitelbaum, Jose L Gallardo, Jessica Bedi, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 30, 2021
Correction to: CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling PathwayElisabet Ampudia-Mesias, Francisco Puerta-Martinez, Miurel Bridges, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 8, 2021
CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling PathwayElisabet Ampudia-Mesias, Francisco Puerta-Martinez, Miurel Bridges, et al.
Vaccine|March 4, 2010
Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapyG Elizabeth Pluhar, Patrick T Grogan, Charlie Seiler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2010
Superior efficacy of tumor cell vaccines grown in physiologic oxygenMichael R Olin, Brian M Andersen, David M Zellmer, et al.
Journal for Immunotherapy of Cancer|May 16, 2014
Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) responseMichael R Olin, Walter Low, David H McKenna, et al.
Journal for Immunotherapy of Cancer|January 20, 2015
CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapyChristopher L Moertel, Junzhe Xia, Rebecca LaRue, et al.
Cancer Research|September 13, 2011
Oxygen is a master regulator of the immunogenicity of primary human glioma cellsMichael R Olin, Brian M Andersen, Adam J Litterman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomasKatherine A Murphy, Melissa G Lechner, Flavia E Popescu, et al.
Expert Review of Clinical Immunology|August 8, 2024
Transcriptomic observations of intra and extracellular immunotherapy targets for pediatric brain tumorsStephen C Frederico, Itay Raphael, Michal Nisnboym, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Cancer Chemotherapy and Pharmacology|March 10, 2012
9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant gliomaAaron M Teitelbaum, Jose L Gallardo, Jessica Bedi, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 30, 2021
Correction to: CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling PathwayElisabet Ampudia-Mesias, Francisco Puerta-Martinez, Miurel Bridges, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 8, 2021
CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling PathwayElisabet Ampudia-Mesias, Francisco Puerta-Martinez, Miurel Bridges, et al.
Vaccine|March 4, 2010
Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapyG Elizabeth Pluhar, Patrick T Grogan, Charlie Seiler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2010
Superior efficacy of tumor cell vaccines grown in physiologic oxygenMichael R Olin, Brian M Andersen, David M Zellmer, et al.
Journal for Immunotherapy of Cancer|May 16, 2014
Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) responseMichael R Olin, Walter Low, David H McKenna, et al.
Journal for Immunotherapy of Cancer|January 20, 2015
CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapyChristopher L Moertel, Junzhe Xia, Rebecca LaRue, et al.
Cancer Research|September 13, 2011
Oxygen is a master regulator of the immunogenicity of primary human glioma cellsMichael R Olin, Brian M Andersen, Adam J Litterman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomasKatherine A Murphy, Melissa G Lechner, Flavia E Popescu, et al.
Expert Review of Clinical Immunology|August 8, 2024
Transcriptomic observations of intra and extracellular immunotherapy targets for pediatric brain tumorsStephen C Frederico, Itay Raphael, Michal Nisnboym, et al.
Pageof 9